Fosinoprilat; Fosinopril diacid; 95399-71-6; Fosinoprilic acid; fosfenopril; Fosinoprilatum; SQ 27,519; SQ-27519; (4S)-4-Cyclohexyl-1-((hydroxy(4-phenylbutyl)phosphinyl)acetyl)-L-proline; PU6BA2D2MD; CHEMBL581; S312EY6ZT8; CHEBI:116962; (2S,4S)-4-cyclohexyl-1-(2-(hydroxy(4-phenylbutyl)phosphoryl)acetyl)pyrrolidine-2-carboxylic acid; SO-27519; L-Proline, 4-cyclohexyl-1-((hydroxy(4-phenylbutyl)phosphinyl)acetyl)-, trans-; 4-Cyclohexyl-1-{2-[hydroxy-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-[2-[hydroxy(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-{2-[hydroxy(4-phenylbutyl)phosphoryl]acetyl}pyrrolidine-2-carboxylic acid; (4S)-4-Cyclohexyl-[(4-phenylbutyl)phosphinyl]acetyl-L-proline; (4S)-4-cyclohexyl-1-{[hydroxy(4-phenylbutyl)phosphoryl]acetyl}-L-proline; L-Proline, 4-cyclohexyl-1-[[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-,(4S)-; Fosinoprilat [USAN:INN]; Fosinoprilatum [INN-Latin]; (2S,4S)-4-cyclohexyl-1-{2-[hydroxy-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid; UNII-S312EY6ZT8; Forsinoprilat; KS8; fosinopril impurity a; SQ-27,519; Fosinoprilat (USAN/INN); FOSINOPRILAT [INN]; FOSINOPRILAT [USAN]; SCHEMBL124537; FOSINOPRIL DIACID [MI]; GTPL6457; DTXSID80869253; ZINC4213382; BDBM50018849; DB14207; SQ27,519; HY-107352; SO 27,519; CS-0028200; C21542; D03772; FOSINOPRIL SODIUM IMPURITY A [EP IMPURITY]; Q27077720; 1[{hydroxy(4-phenylbutyl)phosphinyl}acetyl]-(trans)-4-cyclohexyl-l-proline; trans-4-cyclohexyl-1-[[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-l-proline; L-Proline,4-cyclohexyl-1-[2-[hydroxy(4-phenylbutyl)phosphinyl]acetyl]-,(4S)-; (2S,4S)-4-CYCLOHEXYL-1-((HYDROXY(4-PHENYLBUTYL)PHOSPHORYL)ACETYL)PYRROLIDINE-2-CARBOXYLIC ACID; (2S,4S)-4-cyclohexyl-1-[2-(hydroxy-(4-phenylbutyl)phosphoryl)acetyl]pyrrolidine-2-carboxylic acid